VELA: A first-in-human phase 1/2 study of BLU-222, a potent, selective cyclin-dependent kinase (CDK) 2 inhibitor in patients with cyclin E1 gene (CCNE1)-amplified or CDK4/6 inhibitor-resistant advanced solid tumors

被引：0
|
作者：
Patel, Manish R.
Juric, Dejan
Henick, Brian S.
Moore, Kathleen N.
Do, Doreen
Chapman, Joshua
Zhang, Hui
Roche, Maria
Newberry, Kate J.
Rinne, Mikael
Yap, Timothy A.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-OT3-23-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT3-23-01
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Antitumor Activity of the Cyclin-Dependent Kinase-9 (CDK9) Inhibitor AZD4573 in Relapsed/Refractory Hematological Malignancies: A Phase 1 First-in-Human Study
    Brummendorf, Tim H.
    Medd, Patrick
    Koch, Raphael
    Stilgenbauer, Stephan
    Sharma, Shringi
    He, Yun
    Meyer, Stefanie
    Wey, Margaret C.
    Saeh, Jamal
    Olsson, Richard F.
    Kater, Arnon P.
    BLOOD, 2022, 140 : 3126 - 3127
  • [42] First-in-human phase 1A study of RGT-419B, a next generation CDK4 inhibitor, in patients (pts) with hormone receptor positive (HR+) HER2advanced/metastatic breast cancer (ABC) who progressed on prior CDK4/6 inhibitors (CDK4/6i)
    Wander, Seth
    Valacer, Dave
    Zuniga, Richard
    Yeckes-Rodin, Heather
    Perkins, Christopher
    Ge, Lisa
    Yao, Lili
    Lin, Jing
    Begley, Dawn
    Sun, Feifei
    Zheng, Andie
    Han, Jing
    Xie, Zhi
    Bardia, Aditya
    Kalinsky, Kevin
    CANCER RESEARCH, 2024, 84 (09)
  • [43] Phase I first-in-human study of the polo-like kinase-1 selective inhibitor, GSK461364, in patients with advanced solid tumors
    Olmos, D.
    Allred, A.
    Sharma, R.
    Brunetto, A.
    Smith, D.
    Murray, S.
    Barker, D.
    Taegtmeyer, A.
    de Bono, J.
    Blagden, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [44] A phase I first-in-human study of the polo-like kinase 1-selective inhibitor, GSK461364, in patients with advanced solid tumors
    Blagden, S.
    Olmos, D.
    Sharma, R.
    Barriuso, J.
    Medani, H.
    Versola, M.
    Murray, S.
    Smith, D. A.
    Dar, M. M.
    deBono, J. S.
    EJC SUPPLEMENTS, 2008, 6 (12): : 135 - 136
  • [45] A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors
    Rosen, Lee
    LoRusso, Patricia
    Ma, Wen Wee
    Goldman, Johathan
    Weise, Amy
    Colevas, A. Dimitrios
    Adjei, Alex
    Yazji, Salim
    Shen, Angela
    Johnston, Stuart
    Gates, Mary R.
    Jones, Cheryl
    Musib, Luna
    De Crespigny, Alex
    Chan, Iris
    Sikic, Branimir
    CANCER RESEARCH, 2011, 71
  • [46] Phase 1/2 dose escalation study of NUV-422, a potent inhibitor of cyclin-dependent kinases 2, 4, and 6, in recurrent or refractory (r/r) high-grade gliomas (HGG) and solid tumors
    Wen, Patrick Y.
    Ahnert, Jordi Rodon
    Powderly, John D.
    Colman, Howard
    Matheny, Shannon L.
    Golsorkhi, Anthony A.
    Bihani, Teeru
    Zhang, Yan
    Kaley, Thomas Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] The efficacy and safety of a selective PARP1 inhibitor ACE-86225106 in patients with advanced solid tumors: preliminary results from a first-in-human phase 1/2 study
    Liu, S.
    Zhang, J.
    Chen, Z.
    Zhang, Y.
    Wang, J.
    Chen, Y.
    Chen, J.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S32 - S32
  • [48] A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors
    Lee S. Rosen
    Patricia LoRusso
    Wen Wee Ma
    Jonathan W. Goldman
    Amy Weise
    A. Dimitrios Colevas
    Alex Adjei
    Salim Yazji
    Angela Shen
    Stuart Johnston
    Hsin-Ju Hsieh
    Iris T. Chan
    Branimir I. Sikic
    Investigational New Drugs, 2016, 34 : 604 - 613
  • [49] A first-in-human phase I study to evaluate the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors
    Varga, A.
    Soria, J. C.
    Hollebecque, A.
    LoRusso, P.
    Vaishampayan, U.
    Okrah, K.
    Huang, S. M. A.
    Murray, E.
    Sanabria-Bohorquez, S.
    Tagen, M.
    Dokainish, H.
    Mueller, L.
    Burris, H.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S11 - S11
  • [50] A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
    Varga, Andrea
    Soria, Jean-Charles
    Hollebecque, Antoine
    LoRusso, Patricia
    Bendell, Johanna
    Huang, Shih-Min A.
    Wagle, Marie-Claire
    Okrah, Kwame
    Liu, Lichuan
    Murray, Elaine
    Sanabria-Bohorquez, Sandra M.
    Tagen, Michael
    Dokainish, Hatem
    Mueller, Lars
    Burris, Howard
    CLINICAL CANCER RESEARCH, 2020, 26 (06) : 1229 - 1236
12345